Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 31, Number 2—February 2025
Research

Short-Lived Neutralizing Antibody Responses to Monkeypox Virus in Smallpox Vaccine–Naive Persons after JYNNEOS Vaccination

Kara Phipps, Jennifer Yates, Jessica Pettit, Sean Bialosuknia, Danielle Hunt, Alan P. DuPuis, Anne Payne, William Lee, and Kathleen A. McDonoughComments to Author 
Author affiliation: Wadsworth Center, New York State Department of Health, Albany, New York, USA (K. Phipps, J. Yates, J. Pettit, S. Bialosuknia, D. Hunt, A.P. DuPuis II, A. Payne, W. Lee, K.A. McDonough); University at Albany, Albany (J. Yates, K.A. McDonough)

Main Article

Figure 2

PRNT titers for participants vaccinated with JYNNEOS vaccine up to 6 months prior in a study to assess neutralizing antibody responses to MPXV in smallpox vaccine–naive persons after JYNNEOS vaccination. We used PRNT to test serum samples from donors vaccinated with 2 doses of JYNNEOS vaccine ≈28 days apart. We performed assays with sonicated virus and a 1-hour virus–serum incubation. A) MPXV PRNT50 results; B) VACV PRNT50 results; C) MPXV PRNT90 results; D) VACV PRNT90 results. Participants with no known vaccinia exposure (black circles) are used for mean calculations. Data from a single donor with prior smallpox vaccination (black Xs) are plotted separately and excluded from mean calculations. Each datapoint represents the geometric mean titer of 2 independent experiments, each performed in duplicate. The vertical dotted lines represent the timing of the vaccine doses, and the horizontal dotted lines indicate limits of detection. MPXV, monkeypox virus; prevax, prevaccination; PRNT, plaque reduction neutralization test; PRNT50, 50% plaque reduction as measured by PRNT; PRNT90, 90% plaque reduction as measured by PRNT; VACV, vaccinia virus.

Figure 2. PRNT titers for participants vaccinated with JYNNEOS vaccine up to 6 months prior in a study to assess neutralizing antibody responses to MPXV in smallpox vaccine–naive persons after JYNNEOS vaccination. We used PRNT to test serum samples from donors vaccinated with 2 doses of JYNNEOS vaccine ≈28 days apart. We performed assays with sonicated virus and a 1-hour virus–serum incubation. A) MPXV PRNT50 results; B) VACV PRNT50 results; C) MPXV PRNT90 results; D) VACV PRNT90 results. Participants with no known vaccinia exposure (black circles) are used for mean calculations. Data from a single donor with prior smallpox vaccination (black Xs) are plotted separately and excluded from mean calculations. Each datapoint represents the geometric mean titer of 2 independent experiments, each performed in duplicate. The vertical dotted lines represent the timing of the vaccine doses, and the horizontal dotted lines indicate limits of detection. MPXV, monkeypox virus; prevax, prevaccination; PRNT, plaque reduction neutralization test; PRNT50, 50% plaque reduction as measured by PRNT; PRNT90, 90% plaque reduction as measured by PRNT; VACV, vaccinia virus.

Main Article

Page created: December 11, 2024
Page updated: January 10, 2025
Page reviewed: January 10, 2025
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external